Skip to main content
. Author manuscript; available in PMC: 2017 May 30.
Published in final edited form as: Sci Transl Med. 2017 Feb 1;9(375):eaah3438. doi: 10.1126/scitranslmed.aah3438

Fig. 2. Combination therapy with CTLA4-Ig and an anti-CHIKV human mAb ameliorates acute CHIKV arthritis in mice.

Fig. 2

Mice were inoculated with 103 FFU of CHIKV via a subcutaneous route. (A) Foot swelling (area in square millimeter) from day 0 through day 15 in mice receiving at day 3 a single intraperitoneal injection of 600 μg of isotype control antibody, 300 μg of CTLA4-Ig, 300 μg of anti-CHIKV mAb (4N12), or a combination of 300 μg of CTLA4-Ig and 300 μg of anti-CHIKV mAb. Data are pooled from two independent experiments (n = 15 to 19 animals per group). (B) Representative photographs of ipsilateral foot swelling in the control mAb or combination therapy (CTLA4-Ig + anti-CHIKV mAb) groups. Data represent the means ± SEM. **P < 0.005, ****P < 0.0001 (two-way ANOVA with multiple comparisons).